Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Nov 1;51(11):481-490.
doi: 10.1097/ICL.0000000000001210. Epub 2025 Aug 20.

Efficacy and Safety of Loteprednol Etabonate in Managing Pain and Inflammation After Cataract Surgery: A Systematic Review and Meta-analysis

Abdelrahman M Elettreby  1 , Mohamed A Alsaied, Maab M Saleh, Nasser A Alsabaani, Waleed A Aldhabaan, Saeed Mohammed Abu Sabah, Ahmed A Abo Elnaga
Affiliations
Meta-Analysis

Efficacy and Safety of Loteprednol Etabonate in Managing Pain and Inflammation After Cataract Surgery: A Systematic Review and Meta-analysis

Abdelrahman M Elettreby et al. Eye Contact Lens. .

Abstract

Objectives: This systematic review aims to evaluate loteprednol etabonate's efficacy and safety in reducing post-cataract pain and inflammation.

Methods: A literature search was conducted to identify randomized controlled trials comparing loteprednol etabonate and placebo for post-cataract pain and inflammation. The primary outcome was the proportion of patients with complete resolution of anterior chamber inflammation (ACI) and grade zero pain. The quality of the studies was assessed using the RoB 2 tool, and a meta-analysis was performed using RevMan 5 software.

Results: This systematic review identified eight clinical trials (n=3,332 patients) fulfilling research criteria. Meta-analysis results showed that loteprednol etabonate significantly improved ACI resolution compared with placebo at 8, 15, and 18 days postoperatively (RR=2.25, 2.11, and 2.06, respectively, with a P value <0.00001). Loteprednol etabonate also increased the likelihood of achieving no pain (RR=1.54, 1.66, 1.70, and 1.92, respectively, with a P value <0.00001) and reduced the need for rescue therapy (RR=0.47, P <0.00001) while maintaining no change in IOP after 3, 15, and 18 days.

Conclusion: Loteprednol etabonate demonstrates significant efficacy in alleviating pain and inflammation post-cataract surgery, with notable advantages in safety, including minimal impact on intraocular pressure and reduced adverse events.

Keywords: Anterior chamber inflammation; Cataract surgery; Eye inflammation; Loteprednol.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

References

    1. Thompson J, Lakhani N. Cataracts. Prim Care 2015;42:409–423.
    1. Lam D, Rao SK, Ratra V, et al. Cataract. Nat Rev Dis Primers 2015;1:15014.
    1. Mencucci R, Stefanini S, Favuzza E, et al. Beyond vision: Cataract and health status in old age, a narrative review. Front Med (Lausanne) 2023;10:1110383.
    1. Sabharwal J, Garg AK, Ramulu PY. How much does cataract surgery contribute to intraocular pressure lowering?. Curr Opin Ophthalmol 2024;35:147–154.
    1. Chen X, Xu J, Chen X, et al. Cataract: Advances in surgery and whether surgery remains the only treatment in future. Adv Ophthalmol Pract Res 2021;1:100008.

MeSH terms

LinkOut - more resources